Quetiapine in the Treatment of Anxiety in Patients With Bipolar I or II Depression: A Secondary Analysis From a Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Quetiapine monotherapy shows efficacy in bipolar depression. The analyses in this multicenter, double-blind, randomized, fixed-dose, placebo-controlled study evaluated effects of quetiapine monotherapy on anxiety symptoms in bipolar depression. METHOD: Of 542 outpatients randomly assigned to treatment, 539 with bipolar I (N = 358) or bipolar II (N = 181) disorder experiencing a major depressive episode (DSM-IV) received 8 weeks of quetiapine monotherapy (600 or 300 mg/day) or placebo between September 2002 and October 2003. Anxiety assessments included the Hamilton Rating Scale for Anxiety (HAM-A) and relevant items from the Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HAM-D). Analyses evaluated the pooled dose groups versus placebo. RESULTS: At week 8, quetiapine 600 and 300 mg/day each demonstrated significant improvements in HAM-A total score versus placebo (-10.8 and -9.9 vs. -6.7, p < .001). Quetiapine (pooled doses) significantly improved HAM-A total score from week 1. In bipolar I depression, quetiapine showed significant improvement in HAM-A total score versus placebo (-10.4 vs. -5.1, p < .001). In bipolar I depression, quetiapine also showed significant improvements versus placebo on the HAM-A anxious mood and tension items, HAM-A psychic and somatic subscales, MADRS inner tension item, and HAM-D psychic anxiety item (all p < .001), but not the HAM-D somatic anxiety item. In bipolar II depression, quetiapine reduced the HAM-A total score more than placebo, but the difference was not statistically significant (-9.8 vs. -9.0, p = .473). In bipolar II depression, quetiapine showed significant improvement versus placebo on the HAM-A anxious mood, MADRS inner tension, and HAM-D psychic anxiety items (all p < .01). CONCLUSION: Quetiapine monotherapy shows efficacy in treating anxiety symptoms in bipolar I depression; however, the anxiolytic effects in bipolar II disorder require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, secondary analyses from several RCTs indicate that quetiapine monotherapy significantly reduces symptoms of GAD and panic disorder in patients with bipolar depression.290, 313, 725”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Self-citationAntidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 578
Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia
Pini, S., Cassano, G. B., Simonini, E., Savino, M., Russo, A., & Montgomery, S. A. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)01405-x · Cited by 226
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“orders (see specific disorder sections for evidence), and data show that these agents can significantly reduce anxiety symptoms in patients with bipolar disorder [1409-1413].”
BackgroundYatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
“Two subanalyses of the BOLDER I data showed that among patients with BD II depression, quetiapine was effective in patients with rapid cycling (196), but anxiety scores (HAM-A) were not significantly improved (197).”
MethodMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications
Post, R. M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.09.009 · Cited by 285
“, 2005) and anti-anxiety (Hirschfeld et al., 2006) effects compared with placebo in bipolar depression.”
BackgroundRamasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Bipolar II Disorder: Epidemiology, Diagnosis and Management
Benazzi, F. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00003 · Cited by 179
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
“…and in combination with fluoxetine, were effective in studies of bipolar depression [Calabrese et al., 2005; Tohen et al., 2003] and, more recently, quetiapine monotherapy has demonstrated efficacy in the treatment of anxiety symptoms in patients with bipolar I depression [Hirschfeld et al., 2006].”
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Zuddas, A., Zanni, R., & Usala, T. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.001 · Cited by 132
“…and disruptive behavior disorders appears to be similar to that of valproate alone in bipolar youths (Barzman et al., 2006), but, differently from adults (Hirschfeld et al., 2006; Thase et al., 2006 ), and quetiapine is ineffective in ameliorating depression in adolescents with bipolar depression.”
De Fruyt, J., Deschepper, E., Audenaert, K., Constant, E., Floris, M., Pitchot, W., Sienaert, P., Souery, D., & Claes, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111408461 · Cited by 95
Vázquez, G. H., Baldessarini, R. J., & Tondo, L. (2014) · Depression and Anxiety · doi:10.1002/da.22248 · Cited by 93
“[102, 103] Quetiapine, which has beneficial effects in mania also was effective in depressed bipolar I or II disorder patients.[104] In a recent meta-analytic review, we found that quetiapine was 36% more effective for bipolar depression than placebo, compared to 25% for olanzapine, in five trials of each antipsychoti…”
BackgroundRihmer, Z., & Döme, P. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_4 · Cited by 94
Treatment of bipolar depression: An update
Fountoulakis, K. Ν., Grunze, H., Panagiotidis, P., & Kaprinis, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.016 · Cited by 93
Comorbid Anxiety in Bipolar Disorder Alters Treatment and Prognosis
El‐Mallakh, R. S., & Hollifield, M. A. (2008) · Psychiatric Quarterly · doi:10.1007/s11126-008-9071-5 · Cited by 95
Quetiapine: A Review of its Use in the Management of Bipolar Depression
Sanford, M., & Keating, G. M. (2012) · CNS Drugs · doi:10.2165/11203840-000000000-00000 · Cited by 88
Youssef, N. A., & Rich, C. L. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802177698 · Cited by 68
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69
“Our results with risperidone are inconsistent with earlier analyses showing olanzapine, alone and combined with fluoxetine, and quetiapine alone have anxiolytic properties in bipolar depression (Hirschfeld et al., 2006; Thase et al., 2006; Tohen et al., 2007).”
ResultGrover, M., Dorn, S. D., Weinland, S. R., Dalton, C. B., Gaynes, B. N., & Drossman, D. A. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0723-6 · Cited by 64
“Because mild to moderate somnolence associated with quetiapine usually resolves in 1‐2 weeks [ 16 ], a future goal would be to further counsel patients that this should resolve with time.”
BackgroundPatterns of Quetiapine Use in Psychiatric Inpatients: An Examination of Off-Label Use
Philip, N. S., Mello, K., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230701866870 · Cited by 64
Katzman, M. A., Vermani, M., Jacobs, L., Marcus, M., Kong, B.-G., Lessard, S., Galarraga, W., Struzik, L., & Gendron, A. (2008) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2008.03.002 · Cited by 64
Altamura, A. C., Serati, M., Albano, A., Paoli, R. A., Glick, I. D., & Dell’Osso, B. M. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0196-4 · Cited by 62
Malhi, G. S., Adams, D., Cahill, C. M., Dodd, S., & Berk, M. (2009) · Drugs · doi:10.2165/11318850-000000000-00000 · Cited by 64
Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression
Cantù, F., Ciappolino, V., Enrico, P., Moltrasio, C., Delvecchio, G., & Brambilla, P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.006 · Cited by 55
Cross, A. J., Widzowski, D., Maciag, C. M., Zacco, A., Hudzik, T. J., Liu, J., Nyberg, S., & Wood, M. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13346 · Cited by 50
“…of norquetiapine (Goldstein et al., 2007; Hudzik et al., 2008; Jensen et al., 2008) and quetiapine (Saller and Salama, 1993) and provide a mechanistic basis for the clinical efficacy of quetiapine in mood and anxiety disorders (McIntyre et al., 2005; Hirschfeld et al., 2006; Weisler et al., 2009).”
BackgroundResultInfluentialHamoda, H. M., & Osser, D. N. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802277904 · Cited by 47
Review of atypical antipsychotics in anxiety
Vulink, N. C. C., Figee, M., & Denys, D. A. J. P. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.12.007 · Cited by 47
“patients treated with placebo (Table 1) (Hirschfeld et al. 2006; Tohen et al., 2007).”
ResultSheehan, D. V., Harnett-Sheehan, K., Hidalgo, R. B., Janavs, J., McElroy, S. L., Amado, D., & Suppes, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.016 · Cited by 42
“Previous work has shown that fixed daily doses of 300 and 600 mg quetiapine XR are both effective for anxiety symptoms in bipolar I and II depressive disorders (Hirschfeld et al., 2006), but there is some evidence that bipolar II patients experience more side effects and are more likely to drop out of studies at the h…”
BackgroundResultGarakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328301a74c · Cited by 39
“Major advantages of quetiapine include potential anxiolytic properties, as supported in studies of patients with depression and comorbid anxiety (Hirschfeld et al., 2006; McIntyre et al., 2007).”
BackgroundQuetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-10 · Cited by 35
“BOLDER I trial did not show a statistically significant difference in HAM-A total score from placebo (Hirschfeld et al. 2006), which again may have been due to the smaller number of patients available for analysis.”
ResultSoeiro‐de‐Souza, M. G., Dias, V. V., Missio, G., Balanzá‐Martínez, V., Valiengo, L. D. C. L., Carvalho, A. F., & Moreno, R. A. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2213 · Cited by 40
Rihmer, Z., & FAWCETT, J. A. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch7 · Cited by 35
Emilien, G., Septien, L., Brisard, C., Corruble, E., & Bourin, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.005 · Cited by 46
Adjunctive Use of Atypical Antipsychotics for Treatment‐Resistant Generalized Anxiety Disorder
Lorenz, R. A., Jackson, C. W., & Saitz, M. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.9.942 · Cited by 32
The Comorbidity of Depression and Anxiety Symptoms in Tinnitus Sufferers: A Network Analysis
Chen, X., Ren, L., Xue, X., Yu, N., Liu, P., Shen, W., Zhou, H., Wang, B., Zhou, J., Yang, S., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13040583 · Cited by 34
“There is evidence that olanzapine co-administered with mood stabilizers in patients with agitated mixed states can decrease suicidal ideation [89,90].”
BackgroundKim, S. J., Lee, Y. J., Lee, Y.-J. G., & Cho, S. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.12.032 · Cited by 33
Quetiapine: A Review of its Use in the Treatment of Bipolar Depression
Keating, G. M., & Robinson, D. M. (2007) · Drugs · doi:10.2165/00003495-200767070-00008 · Cited by 30
Quetiapine monotherapy for bipolar depression
Thase, M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1162 · Cited by 34
“…was associated with a rapid and pronounced improvement across individual and combined quetiapine treatment groups compared with placebo ( − 10.3 versus − 6.7 for combined quetiapine and placebo groups, respectively), irrespective of baseline severity of depression (Hirschfeld et al 2006).”
InfluentialImplementing clinical guidelines for bipolar disorder
Morriss, R. K. (2008) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1348/147608308x278105 · Cited by 29
Lydiard, R. B., Culpepper, L., Schiöler, H., Gustafsson, U., & Paulsson, B. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08m00659 · Cited by 23
“These results are similar to those found in an initial secondary analysis of the first (BOLDER I) study data.(27) Few studies have examined whether treatment with atypical antipsychotics can lessen the severity of bipolar disorder and improve anxiety symptoms or disorders.”
ResultThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Loebel, A. D., Koblan, K. S., Tsai, J., Deng, L., Fava, M., KENT, J. M., & Hopkins, S. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.109 · Cited by 22
Safety and Efficacy of Quetiapine in Bipolar Depression
Bogart, G. T., & Chavez, B. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m193 · Cited by 26
Wang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
Baune, B. T. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3238 · Cited by 27
“Quetiapine has demonstrated clinical efficacy in the past few years for clinical indications ranging from bipolar disorder (Berk and Dodd 2005; Calabrese et al 2005; Croissant et al 2006) and treatment of behavioral disturbances in dementia (Savaskan et al 2006) to the management of substance dependence disorders (Sat…”
Subjective wellbeing under quetiapine treatment: Effect of diagnosis, mood state, and anxiety
Lambert, M., Naber, D., Karow, A., Huber, C. G., Köhler, J., Heymann, J., & SCHIMMELMANN, B. G. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.004 · Cited by 22
“antidepressive, mood-stabilizing, and anxiolytic effects (e.g., Dorée et al., 2007; Hirschfeld et al., 2006; Keating and Robinson, 2007).”
BackgroundSUICIDE AND ANXIETY IN DSM-5: The Cutting Edge: Suicide and Anxiety in DSM-5
Fawcett, J. (2013) · Depression and Anxiety · doi:10.1002/da.22058 · Cited by 18
Lateral hypothalamic kindling induces manic-like behavior in rats: a novel animal model
Abulseoud, O. A., Çamsarı, U. M., Ruby, C. L., Mohamed, K., Gawad, N. A., Kasasbeh, A. S., Yüksel, M. Y., & Choi, D. (2014) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0007-8 · Cited by 21
“The acute manic episode, the hallmark of bipolar disorder, is a medical emergency that frequently requires hospitalization (Hirschfeld et al. 2006).”
BackgroundComorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale
Kinrys, G., Bowden, C. L., Nierenberg, A. A., Hearing, C. M., Gold, A. K., Rabideau, D. J., Sylvia, L. G., Gao, K., Kamali, M., Bobo, W. V., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.039 · Cited by 20
Jain, R., McIntyre, R. S., Cutler, A. J., Earley, W. R., Nguyen, H., Adams, J., & Yatham, L. N. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000500 · Cited by 20
“…, 2005; Thase et al. , 2006; Loebel et al. , 2014a, 2014b; Earley et al. , 2019, 2020a) and secondary post hoc analyses have shown that quetiapine (Hirschfeld et al. , 2006; Lydiard et al. , 2009), olanzapine-fluoxetine combination, olanzapine (Tohen et al. , 2007), and lurasidone (Cucchiaro et…”
ResultBandelow, B., Bauer, M., Vieta, E., El-Khalili, N., Gustafsson, U., Earley, W. R., & Eriksson, H. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.842654 · Cited by 18
“Quetiapine immediate release (300 and 600 mg) once daily monotherapy has demonstrated signifi cant effi cacy in the treatment of anxiety in patients with bipolar depression, as assessed using the HAM-A (Week 8 change, 9.9 and 10.8 vs. 6.7 for placebo, respectively; P 0.001) (Hirschfeld et al. 2006).”
MethodInfluentialBipolar II Disorder: Current and Future Treatment Options
El‐Mallakh, R. S., Weisler, R. H., Townsend, M. H., & Ginsberg, L. D. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600948480 · Cited by 18
Self-citationUpdate on extended release quetiapine fumarate in schizophrenia and bipolar disorders
El-Khalili, N. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s14369 · Cited by 19
Management of Bipolar II Disorder
Wong, M. M. C. (2011) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.85391 · Cited by 17
“[45] Two subanalyses of the BOLDER I data showed that among patients with BP II depression, quetiapine was effective in patients with rapid cycling,[46] but anxiety scores (HAM-A) were not significantly improved.[47] However, in the pooled analysis of BOLDER I and II, the changes in HAM-D, HAM-A, and CGI were signific…”
MethodAnsari, A., & Osser, D. N. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673220903523524 · Cited by 20
Dannlowski, U., Baune, B. T., Böckermann, I., Domschke, K., Evers, S., Arolt, V., Hetzel, G., & Rothermundt, M. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.963 · Cited by 18
“, 2006) and anxiety symptoms in depression (Hirschfeld et al., 2006).”
BackgroundCrapanzano, C., Damiani, S., & Guiot, C. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001420 · Cited by 16
“…Selective Outcome Reporting Other Source of Bias Calabrese et al, 2005 Low Low Low Low Low Low Low Thase et al, 2006 Low Low Low Low Low Low Low Hirschfeld et al, 2006 Low Low Low Low Low Low Low Vieta et al, 2007 Low Low Low Low Low Low Low McIntyre et al, 2007 Low Low Low Low Low Low High…”
BackgroundResultInfluentialCullen, C., Kappelmann, N., Umer, M., Abdolizadeh, A., Husain, M. O., Bonato, S., Sharma, G. K., Xue, S., Ortiz, A., Kloiber, S. M., et al. (2021) · Bipolar Disorders · doi:10.1111/bdi.13125 · Cited by 16
Advances in Treatment of Bipolar Disorders
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210 · Cited by 15
Atik, L., Erdoğan, A., Karaahmet, E., Saraçlı, Ö., Atasoy, N., Kurçer, M. A., & Balcıoğlu, İ. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.12.031 · Cited by 12
Quetiapine monotherapy for bipolar depression
Janicak, P. G., & Rado, J. T. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585461 · Cited by 12
The role of quetiapine extended release in the treatment of bipolar depression
Cristancho, M., & Thase, M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0067-9 · Cited by 14
Psychopharmacology: A house divided
Dean, C. E. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.028 · Cited by 13
Bipolar disorder and anxiety disorders.
Látalová, K., Praško, J. P., Grambal, A., Havlikova, P., Jelenova, D., Mainerová, B., Kamarádová, D., Ocisková, M., Sedlackova, Z., & Sandoval, A. (2013) · PubMed · Cited by 13
Anxiety and bipolar disorders: epidemiological and clinical aspects
Maina, G., Rosso, G., Aguglia, A., Chiodelli, D. F., & Bogetto, F. (2011) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 15
Schaffer, A., McIntosh, D., Goldstein, B. I., Rector, N. A., McIntyre, R. S., Beaulieu, S., Swinson, R., & Yatham, L. N. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400103 · Cited by 7
Goldberg, J. F., SIU, C. O., Tocco, M., Pikalov, A., & Loebel, A. D. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14732 · Cited by 8
Bauer, M., Glenn, T., Grof, P., Rasgon, N., Marsh, W., Sagduyu, K., Alda, M., Lewitzka, U., Schmid, R., & Whybrow, P. C. (2009) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500802450514 · Cited by 6
Comorbid Anxiety and Suicide in Mood Disorders
FAWCETT, J. A. (1997) · Psychiatric Annals · doi:10.3928/0048-5713-19971002-01 · Cited by 5
Seo, J. S., Jamieson, K., Cosgrove, V. E., Gwizdowski, I. S., Yang, H., Sheehan, D. V., McElroy, S. L., & Suppes, T. M. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.001 · Cited by 6
“Olanzapine alone or with fluoxetine [42], and quetiapine [11], were better than placebo (PBO) in reducing scores on an anxiety measure in individuals with BD depression.”
BackgroundWu, J., Kwan, A. T. H., Rhee, T. G., Ho, R., d’Andrea, G., Martinotti, G., Teopiz, K. M., Ceban, F., & McIntyre, R. S. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274538 · Cited by 3
“Observed EPSE indicates the fact that LB-102 exhibits greater D 2 receptor occupancy at lower doses, as 600 mg amisulpride is required to achieve over 80% dopamine occupancy in the early study [36].”
BackgroundComorbid Anxiety and Suicide in Mood Disorders
(2007) · Psychiatric Annals · doi:10.3928/00485713-20071001-03 · Cited by 4
Carlborg, A., Thuresson, M., Ferntoft, L., & Bodegård, J. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314560740 · Cited by 3
Atypical Antipsychotics for Bipolar Disorder: Overblown or Blown Over?
Ng, F., Dodd, S., & Berk, M. (2007) · Deakin Research Online (Deakin University) · Cited by 2
Practical management of cyclothymia
Perugi, G., & Popović, D. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511776922.014 · Cited by 2
Catts, S. V., Frost, A. D. J., Gifford, S., & Scott, J. G. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500701496733 · Cited by 2
“It is anxiolytic [6,7] and has antiaggression [8,9] effects.”
BackgroundThe anxious bipolar phenotype: clinical complexity and treatment response
Singh, B., Ho, A. M., Coombes, B. J., Romo‐Nava, F., Barboza, A. B. C., Gardea‐Resendez, M., Bond, D. J., Prieto, M. L., Veldić, M., Pendegraft, R., et al. (2026) · International Journal of Bipolar Disorders · doi:10.1186/s40345-026-00415-z · Cited by 1
“Short-term (8 weeks) data support quetiapine as a helpful option for BD + ANX (Hirschfeld et al. 2006; Sheehan et al. 2013).”
Pharmacotherapy Update: Quetiapine use in Bipolar Disorder—What does the evidence tell us?
Taylor, M., Mackay, K., & Shajahan, P. M. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1136 · Cited by 1
Clinical models for managing Bipolar II disorder: model 2
Ketter, T. A., & Wang, P. W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003315.019 · Cited by 1
The use of atypical antipsychotic drugs in Bipolar II Disorder
Fresno, D., & Vieta, E. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544187.012 · Cited by 1
Mc, M., Rovera, C., Ciappolino, V., Di Pace, C., Paletta, S., Reggiori, A., & Ac, A. (2016) · Dual Diagnosis Open Access · doi:10.21767/2472-5048.100021 · Cited by 1
Introduction — Advancing understanding of the effectiveness of quetiapine in acute mania
Ketter, T. A. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.003 · Cited by 1
Benazzi, F. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544187.019 · Cited by 1
Ketter, T. A., & Wang, P. W. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544187.018
Quetiapine in Bipolar Disorder
Kunz, M., Nyberg, S., & Yatham, L. N. (2011) · Wiley eBooks · doi:10.1002/9780470975114.ch10
The acute treatment of bipolar depression: Historically relevant and recent controlled trials
Kronstein, P. D., & Zarate, C. A. (2006) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629389
“In a follow-up paper, Hirschfeld et al. [ 38 ] pooled the two dose groups and found that at week 8, in the bipolar I (but not bipolar II) subgroup, quetiapine demonstrated a significant improvement on most anxiety measures as compared to placebo.”
BackgroundRecent Progress in the Pharmacotherapy of Bipolar Disorder
Mitchell, P. B., Loo, C. K. A., & Breakspear, M. J. (2009) · Future Neurology · doi:10.2217/fnl.09.18
Revisión de los antipsicóticos atípicos en la ansiedad
Vulink, N. C. C., Figee, M., & Denys, D. A. J. P. (2012) · Psiquiatría Biológica · doi:10.1016/j.psiq.2012.10.002
Disturbi bipolari e d'ansia: aspetti epidemiologici e clinici
Maina, G., Rosso, G., Aguglia, A., Chiodelli, D. F., & Bogetto, F. (2011) · CINECA IRIS Institutial Research Information System (University of Genoa) · Cited by 2
Koslow, S. H., Ruiz, P., & Nemeroff, C. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139519502.012
Drug treatment of secondary schizophrenia
Jibson, M. D., & Tandon, R. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511789977.033
Quetiapine Review of its Use in the Management of
Cassidy, F., Psychiatry, C., Menke, A., & Suzuki, T. (2012)
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as04
(2006) · Evidence-Based Mental Health · doi:10.1136/ebmh.9.3.64
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as06
(2006) · Evidence-Based Mental Health · doi:10.1136/ebmh.9.4.92
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as04
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as06
Anxiety: Its Management, Treatment, and Alternative Complementary Medicine
Uppalwar, S. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822265289240306175345
Metadata
- Authors
- Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- University of North Carolina at Chapel Hill (US)
- AstraZeneca (United Kingdom) (GB)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-03-15
- Volume
- 67
- Issue
- 03
- Pages
- 355-362
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2093305066
- Cited by
- 116
- References
- 23
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 5 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2016: 2 · 2015: 13 · 2014: 7 · 2013: 3 · 2012: 9
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- quetiapine, bipolar depression, bipolar I disorder, bipolar II disorder, anxiety symptoms, anxiolytic effects, major depressive episode, Hamilton Anxiety Rating Scale, inner tension
- MeSH terms
- Quetiapine Fumarate, Adult, Ambulatory Care, Anxiety Disorders, Bipolar Disorder, Major Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Placebos, Psychiatric Status Rating Scales, Antipsychotic Agents, Comorbidity, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.